A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases

The development of broad-spectrum antivirals against human coronaviruses (HCoVs) is critical to combat the current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, as well as future outbreaks of emerging CoVs. We ha...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Jie Zhou, Wei Xu, Zezhong Liu, Chao Wang, Shuai Xia, Qiaoshuai Lan, Yanxing Cai, Shan Su, Jing Pu, Lixiao Xing, Youhua Xie, Lu Lu, Shibo Jiang, Qian Wang
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2022-04-01
Saila:	Acta Pharmaceutica Sinica B
Gaiak:	Coronavirus Lipopeptide SARS-CoV-2 Polyethylene glycol Fusion inhibitor
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2211383521002756
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!